Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Autor: Arend RC; University of Alabama at Birmingham School of Medicine, Birmingham, AL., Monk BJ; HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ., Shapira-Frommer R; Chaim Sheba Medical Center, Ramat Gan, Israel., Haggerty AF; Hospital of the University of Pennsylvania, Philadelphia, PA., Alvarez EA; University of California, San Francisco, CA., Amit A; Rambam Health Care Campus, Haifa, Israel., Alvarez Secord A; Duke Cancer Institute, Duke University Health System, Durham, NC., Muller C; University of New Mexico, Albuquerque, NM., Casado Herraez A; San Carlos University Teaching Hospital, Madrid, Spain., Herzog TJ; University of Cincinnati Cancer Center, University of Cincinnati, Cincinnati, OH., Tewari KS; University of California, Medical Center, Orange, CA., Cohen JG; Department of Surgery, City of Hope, Irvine, CA., Huang M; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Yachnin A; Kaplan Medical Center, Rehovot, Israel., Holeman LL; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK., Ledermann JA; UCL Cancer Institute, University College London, London, United Kingdom., Rachmilewitz Minei T; VBL Therapeutics, Modiin, Israel., Buyse M; International Drug Development Institute, Louvain-la-Neuve, Belgium., Fain Shmueli S; VBL Therapeutics, Modiin, Israel., Lavi M; VBL Therapeutics, Modiin, Israel., Harats D; VBL Therapeutics, Modiin, Israel., Penson RT; Massachusetts General Hospital, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jan 10; Vol. 42 (2), pp. 170-179. Date of Electronic Publication: 2023 Oct 31.